Crescent Biopharma (CBIO) Competitors $13.29 +0.27 (+2.07%) As of 07/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesSEC FilingsSustainabilityTrendsBuy This Stock CBIO vs. GERN, ZBIO, RGLS, LXRX, MYGN, EBS, RIGL, XOMA, VSTM, and VNDAShould you be buying Crescent Biopharma stock or one of its competitors? The main competitors of Crescent Biopharma include Geron (GERN), Zenas BioPharma (ZBIO), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Verastem (VSTM), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. Crescent Biopharma vs. Its Competitors Geron Zenas BioPharma Regulus Therapeutics Lexicon Pharmaceuticals Myriad Genetics Emergent Biosolutions Rigel Pharmaceuticals XOMA Royalty Verastem Vanda Pharmaceuticals Crescent Biopharma (NASDAQ:CBIO) and Geron (NASDAQ:GERN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment. Do insiders & institutionals hold more shares of CBIO or GERN? 75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 8.7% of Crescent Biopharma shares are owned by company insiders. Comparatively, 7.4% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has preferable valuation & earnings, CBIO or GERN? Crescent Biopharma has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrescent Biopharma$10K25,981.95-$37.88M-$46.00-0.29Geron$76.99M10.42-$174.57M-$0.21-6.00 Do analysts rate CBIO or GERN? Crescent Biopharma presently has a consensus target price of $25.67, suggesting a potential upside of 93.13%. Geron has a consensus target price of $4.61, suggesting a potential upside of 265.96%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than Crescent Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crescent Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Geron 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has more risk and volatility, CBIO or GERN? Crescent Biopharma has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Geron has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Does the media refer more to CBIO or GERN? In the previous week, Geron had 6 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Geron and 1 mentions for Crescent Biopharma. Crescent Biopharma's average media sentiment score of 0.93 beat Geron's score of 0.21 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Overall Sentiment Crescent Biopharma Positive Geron Neutral Is CBIO or GERN more profitable? Crescent Biopharma has a net margin of 0.00% compared to Geron's net margin of -119.54%. Geron's return on equity of -47.86% beat Crescent Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Crescent BiopharmaN/A -293.92% -206.20% Geron -119.54%-47.86%-26.78% SummaryCrescent Biopharma beats Geron on 10 of the 17 factors compared between the two stocks. Get Crescent Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBIO vs. The Competition Export to ExcelMetricCrescent BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$259.82M$2.51B$5.72B$9.53BDividend YieldN/A1.77%4.70%4.06%P/E Ratio-0.299.3828.4020.09Price / Sales25,981.95749.72460.13104.16Price / CashN/A23.3925.1828.38Price / Book1.615.168.625.86Net Income-$37.88M$31.24M$3.25B$259.11M7 Day Performance0.68%6.98%3.59%1.88%1 Month Performance-16.42%19.78%11.71%12.31%1 Year PerformanceN/A-1.37%35.36%17.86% Crescent Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBIOCrescent Biopharma3.1909 of 5 stars$13.29+2.1%$25.67+93.1%N/A$259.82M$10K-0.2950GERNGeron3.3574 of 5 stars$1.28+3.7%$4.61+261.7%-73.0%$805.70M$76.99M-6.0270ZBIOZenas BioPharma1.6504 of 5 stars$14.30+0.1%$36.67+156.4%N/A$598.23M$15M-4.03N/ARGLSRegulus Therapeutics1.4755 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830LXRXLexicon Pharmaceuticals2.3815 of 5 stars$1.18-4.5%$3.67+212.1%-54.0%$424.75M$31.08M-2.30140MYGNMyriad Genetics4.6755 of 5 stars$4.53+1.7%$14.38+217.9%-83.9%$417.12M$837.60M-4.042,700Positive NewsEBSEmergent Biosolutions4.4711 of 5 stars$7.00+0.8%$14.33+104.9%-48.9%$379.69M$1.04B-2.582,420Positive NewsRIGLRigel Pharmaceuticals3.3328 of 5 stars$20.10+2.6%$36.40+81.1%+87.6%$358.83M$179.28M9.70160Positive NewsXOMAXOMA Royalty4.0109 of 5 stars$25.65+0.6%$69.50+171.0%-11.7%$306.49M$28.49M-22.2710Analyst UpgradeVSTMVerastem3.5192 of 5 stars$5.15+0.9%$13.38+160.0%+107.4%$282.72M$10K-1.6150VNDAVanda Pharmaceuticals4.7355 of 5 stars$4.70+0.8%$16.50+251.4%-23.3%$276.68M$198.77M-6.26290Upcoming Earnings Related Companies and Tools Related Companies Geron Competitors Zenas BioPharma Competitors Regulus Therapeutics Competitors Lexicon Pharmaceuticals Competitors Myriad Genetics Competitors Emergent Biosolutions Competitors Rigel Pharmaceuticals Competitors XOMA Royalty Competitors Verastem Competitors Vanda Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBIO) was last updated on 7/28/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA grave, grave error.Nvidia just hit $4 trillion… but a tech apocalypse may already be underway. A controversial new documentary...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
